Effectiveness and Tolerability of A Polymyxin B Dosing Protocol-Reference-Cited by-同舟云学术

Effectiveness and Tolerability of A Polymyxin B Dosing Protocol

Published:2012-03 Issue:3 Volume:46 Page:455-456
ISSN:1060-0280
Container-title:Annals of Pharmacotherapy
language:en
Short-container-title:Ann Pharmacother

Author:

Esaian Diana¹,Dubrovskaya Yanina²,Phillips Michael³,Papadopoulos John⁴

Affiliation:

1. Division of Pharmacotherapy Department of Pharmacy New York University Langone Medical Center New York, NY

2. Division of Pharmacotherapy Department of Pharmacy New York University Langone Medical Center

3. Department of Infection Control and Prevention New York University Langone Medical Center Clinical Assistant Professor Division of Infectious Diseases Department of Medicine New York University School of Medicine New York, NY

4. Critical Care Pharmacist Division of Pharmacotherapy Department of Pharmacy New York University Langone Medical Center Clinical Assistant Professor of Medicine Department of Medicine New York University School of Medicine Associate Professor of Pharmacy Practice Arnold & Marie Schwartz College of Pharmacy Brooklyn, NY

Publisher

SAGE Publications

Subject

Pharmacology (medical)

Link

http://journals.sagepub.com/doi/pdf/10.1345/aph.1Q294

Reference5 articles.

1. Pharmacodynamics of Polymyxin B against Pseudomonas aeruginosa

2. Infectious Diseases: Parenteral Polymyxin B Use in Patients with Multidrug-Resistant Gram-Negative Bacteremia and Urinary Tract Infections: A Retrospective Case Series

3. Rapidly Rising Prevalence of Nosocomial Multidrug-Resistant, Gram-Negative Bacilli: A 9-Year Surveillance Study

4. Definition and Classification of Acute Kidney Injury

5. Carbapenem-resistant Klebsiella pneumoniae bacteremia: factors correlated with clinical and microbiologic outcomes

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Understanding the Harmful Impact of Polymyxins on Acinetobacter baumannii;Acinetobacter baumannii - The Rise of a Resistant Pathogen [Working Title];2023-12-12

2. Mid‐dosing interval concentration is important for polymyxin B exposure and acute kidney injury in critically ill patients;CPT: Pharmacometrics & Systems Pharmacology;2023-09-17

3. Population pharmacokinetics and limited sampling strategies of polymyxin B in critically ill patients;Journal of Antimicrobial Chemotherapy;2023-01-26

4. Risk of polymyxin B-induced acute kidney injury with a non adjusted dose versus adjusted dose based on renal function;Personalized Medicine;2022-07

5. Does Monitoring Total and Free Polymyxin B1 Plasma Concentrations Predict Polymyxin B-Induced Nephrotoxicity? A Retrospective Study in Critically Ill Patients;Infectious Diseases and Therapy;2022-06-11